These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 37240930)

  • 1. Oral Health of Patients Undergoing Percutaneous Coronary Intervention-A Possible Link between Periodontal Disease and In-Stent Restenosis.
    Nagy FT; Gheorghita D; Dharmarajan L; Braunitzer G; Achim A; Ruzsa Z; Antal MÁ
    J Pers Med; 2023 Apr; 13(5):. PubMed ID: 37240930
    [No Abstract]   [Full Text] [Related]  

  • 2. Procedural Results and Long-Term Outcomes of Percutaneous Coronary Intervention for in-Stent Restenosis Chronic Total Occlusion Compared with de novo Chronic Total Occlusion.
    Tang G; Zheng N; Yang G; Li H; Ai H; Zhao Y; Sun F; Zhang H
    Int J Gen Med; 2021; 14():5749-5758. PubMed ID: 34552350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiographic and clinical outcome of percutaneous coronary intervention for in-stent restenosis of bifurcated lesions.
    Coroleu SF; De Vita M; Burzotta F; Trani C; Porto I; Niccoli G; Leone AM; Tommasino A; Talarico GP; Schiavoni G; Crea F
    EuroIntervention; 2012 Oct; 8(6):701-7. PubMed ID: 23086788
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive analysis of predictive factors for rapid angiographic stenotic progression and restenosis risk in coronary artery disease patients underwent percutaneous coronary intervention with drug-eluting stents implantation.
    Wu Y; Fu X
    J Clin Lab Anal; 2019 Feb; 33(2):e22666. PubMed ID: 30221497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence of Restenosis Following Rapamycin or Paclitaxeleluting Stent in Coronary Stent Implantation.
    Shakarami A
    Cardiovasc Hematol Disord Drug Targets; 2021; 21(3):196-201. PubMed ID: 34886782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk factors of in-stent restenosis among coronary artery disease patients with syphilis undergoing percutaneous coronary intervention: a retrospective study.
    Zhang L; Wang Y; Zhang Z; Liang H; Wu L; Ni L; Gao G; Yang D; Zhao H; Xiao J
    BMC Cardiovasc Disord; 2021 Sep; 21(1):438. PubMed ID: 34525967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Periodontal Disease on Long-Term Outcomes After Percutaneous Coronary Intervention for De Novo Coronary Lesions in Non-Smokers.
    Fukushima T; Yonetsu T; Aoyama N; Tashiro A; Niida T; Shiheido-Watanabe Y; Maejima Y; Isobe M; Iwata T; Sasano T
    Circ J; 2022 Apr; 86(5):811-818. PubMed ID: 34789614
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of clinical outcomes between percutaneous coronary intervention for de novo lesions versus in-stent restenosis lesions.
    Takeuchi M; Dohi T; Fukase T; Nishio R; Takahashi N; Endo H; Doi S; Kato Y; Okai I; Iwata H; Okazaki S; Isoda K; Miyauchi K; Minamino T
    Cardiovasc Interv Ther; 2022 Apr; 37(2):324-332. PubMed ID: 34224098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New predictors of in-stent restenosis in patients with diabetes mellitus undergoing percutaneous coronary intervention with drug-eluting stent.
    Wang JL; Qin Z; Wang ZJ; Shi DM; Liu YY; Zhao YX; Yang LX; Cheng WJ; Zhou YJ
    J Geriatr Cardiol; 2018 Feb; 15(2):137-145. PubMed ID: 29662507
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FGF-23 correlates with endocrine and metabolism dysregulation, worse cardiac and renal function, inflammation level, stenosis degree, and independently predicts in-stent restenosis risk in coronary heart disease patients underwent drug-eluting-stent PCI.
    Song T; Fu Y; Wang Y; Li W; Zhao J; Wang X; Wang H; Zhao Y; Fu X
    BMC Cardiovasc Disord; 2021 Jan; 21(1):24. PubMed ID: 33413149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adiponectin and insulin resistance are related to restenosis and overall new PCI in subjects with normal glucose tolerance: the prospective AIRE Study.
    Sasso FC; Pafundi PC; Marfella R; Calabrò P; Piscione F; Furbatto F; Esposito G; Galiero R; Gragnano F; Rinaldi L; Salvatore T; D'Amico M; Adinolfi LE; Sardu C
    Cardiovasc Diabetol; 2019 Mar; 18(1):24. PubMed ID: 30832662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk factors for in-stent restenosis after coronary stent implantation in patients with coronary artery disease: A retrospective observational study.
    Zhang J; Zhang Q; Zhao K; Bian YJ; Liu Y; Xue YT
    Medicine (Baltimore); 2022 Nov; 101(47):e31707. PubMed ID: 36451388
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk factors associated with intra-stent restenosis after percutaneous coronary intervention.
    Alexandrescu DM; Mitu O; Costache II; Macovei L; Mitu I; Alexandrescu A; Georgescu CA
    Exp Ther Med; 2021 Oct; 22(4):1141. PubMed ID: 34504587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A predictive model involving serum uric acid, C-reactive protein, diabetes, hypercholesteremia, multiple lesions for restenosis risk in everolimus-eluting stent-treated coronary heart disease patients.
    Feng Q; Zhao Y; Wang H; Zhao J; Wang X; Shi J
    Front Cardiovasc Med; 2022; 9():857922. PubMed ID: 36035940
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of stent length on restenosis in patients with acute myocardial infarction treated with primary percutaneous coronary intervention: analysis based on data from the Trial to Assess the Use of the Cypher Stent in Acute Myocardial Infarction Treated with Balloon Angioplasty (TYPHOON).
    Rozenman Y; Witzling V; Tamari I; Turkisher V; Kriviski M; Bode C; Henry P; Teiger E; Cebrian A; Stoll HP; Spaulding C
    EuroIntervention; 2009 Jun; 5(2):219-23. PubMed ID: 19527979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The independent value of a direct stenting strategy on early and late clinical outcomes in patients undergoing elective percutaneous coronary intervention.
    Sardi GL; Laynez-Carnicero A; Torguson R; Xue Z; Suddath WO; Kent KM; Satler LF; Pichard AD; Lindsay J; Waksman R
    Catheter Cardiovasc Interv; 2013 May; 81(6):949-56. PubMed ID: 22888029
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug-eluting balloon (DEB) for de-novo coronary artery disease and in-stent restenosis: immediate and intermediate term results from a prospective registry.
    Ahmed W; Shah MA; Thaver AM; Mirza J
    J Pak Med Assoc; 2011 Feb; 61(2):157-60. PubMed ID: 21375166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pilot study of oral rapamycin to prevent restenosis in patients undergoing coronary stent therapy: Argentina Single-Center Study (ORAR Trial).
    Rodriguez AE; Alemparte MR; Vigo CF; Pereira CF; Llaurado C; Russo M; Virmani R; Ambrose JA
    J Invasive Cardiol; 2003 Oct; 15(10):581-4. PubMed ID: 14519892
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effects of miRNA-1,miRNA-21 in plasma on in-stent restenosis in patients with coronary heart disease and diabetes mellitus after percutaneous coronary intervention].
    Guan JJ; Zhang Y; Liu YJ
    Zhongguo Ying Yong Sheng Li Xue Za Zhi; 2018 Apr; 34(4):304-308 384. PubMed ID: 30788936
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Occurrence and predictive factors of restenosis in coronary heart disease patients underwent sirolimus-eluting stent implantation.
    Zhao J; Wang X; Wang H; Zhao Y; Fu X
    Ir J Med Sci; 2020 Aug; 189(3):907-915. PubMed ID: 31989420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.